Intelligence · Patents
Patents expiring in 2033
Annual patent cliff calendar for 2033 — US pharmaceutical patents by expiration date.
- Patents
- 1,330
Quick answer
1,330 indexed pharmaceutical patents have expiration dates in 2033. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8501722
Methods and compositions for treating bacterial infection
granted -
US 8501804
Bicyclic compound
granted -
US 8501188
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
granted -
US 8501191
FGFR2-IIIb fusion proteins and methods of making them
granted -
US 8501229
Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
granted -
US 8501194
Vaccine for viruses that cause persistent or latent infections
granted -
US 8501404
Gnaq mutations in melanoma
granted -
US 8501423
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
granted -
US 8501678
Variant activin receptor polypeptides and uses thereof
granted -
US 8501466
Vector
granted -
US 8501681
Macrocyclic hepatitis C virus serine protease inhibitors
granted -
US 8501682
Difluorinated tripeptides as HCV serine protease inhibitors
granted -
US 8501692
Compositions and methods for altering cocaine esterase activity
granted -
US 8501705
Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
granted -
US 8501695
Tissue kallikrein for the treatment of diseases associated with amyloid protein
granted -
US 8501688
SCGB3A2 as a growth factor and anti-apoptotic agent
granted -
US 8501704
Immunosuppression compound and treatment method
granted -
EP 2623110
Faktor-XII-Hemmer zur Behandlung neurologischer Entzündungserkrankungen
granted -
US 8507524
Modulators of ATP-binding cassette-transporters
granted -
US 8507463
Nucleotide analogue prodrug and the preparation thereof
granted -
US 8507534
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
granted -
US 8507445
Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
granted -
US 8507437
Apoptosis-modulating p53 protein therapy for vascular disorders and nanoparticles containing the same
granted -
US 8507206
Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
granted -
US 8507435
Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
granted -
US 8507433
Cardioprotective effects of GHRH agonists
granted -
US 8507195
MiRNAs dysregulated in triple-negative breast cancer
granted -
US 8506961
Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus (JEV) and their use
granted -
US 8506959
Prevention and treatment of synucleinopathic and amyloidogenic disease
granted -
US 8506947
Vaccinia virus expression vector for selective replication in a tumor cell and introduction of exogenous nucleotide sequence into a tumor cell
granted -
US 8506928
Methods and compounds for targeting tissues
granted -
US 8507012
Formulations comprising extracts from primitive plant species (mosses, ferns and lichens) to treat and prevent cancers
granted -
US 8507447
Treatments for gastrointestinal disorders
granted -
US 8507551
Antimicrobial therapy for bacterial infections
granted -
US 8507672
Substituted pyrrolo[2,3-d]pyrimidines as LIM kinase 2 inhibitors
granted -
US 8506944
Replenishment and enrichment of ocular surface lubrication
granted -
US 8507663
Compositions and methods for inhibiting expression of CD274/PD-L1 gene
granted -
US 8507687
Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
granted -
US 8507675
Compositions and methods for inhibition of the JAK pathway
granted -
US 8507661
Modified iRNA agents
granted -
US 8507650
Use of bacteriophage outer membrane breaching proteins expressed in plants for the control of gram-negative bacteria
granted -
US 8507552
Triptolide prodrugs
granted -
US 8507653
Factor IX moiety-polymer conjugates having a releasable linkage
granted -
US 8507536
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
granted -
US 8507522
Hepatitis C virus inhibitors
granted -
US 8507455
Folate conjugates
granted -
EP 2624836
BEPOTASTIN-ZUSAMMENSETZUNG
granted -
US 2013210912
Ophthalmic Pharmaceutical Compositions and Methods of Making and Using Same
granted
Frequently asked questions
How many pharma patents expire in 2033?
1,330 published patents in our USPTO index have expiration dates falling in calendar year 2033.